open access

Vol 1, No 2 (2012)
Review articles (submitted)
Published online: 2012-06-01
Get Citation

Linagliptin — new DPP-4 inhibitor. How much novelty does it bring to clinical practice?

Maciej Pawłowski, Małgorzata Gilewska, Leszek Czupryniak
Diabetologia Kliniczna 2012;1(2):71-76.

open access

Vol 1, No 2 (2012)
Review articles (submitted)
Published online: 2012-06-01

Abstract

Preservation of insulin secretion in beta cells is oneof the objectives of type 2 diabetes treatment. Useof incretin-based drugs offers such possibilities. Thedipeptidyl peptidase 4 (DPP-4) inhibitors, the newclass of antidiabetic drugs, increases level of plasmaendogenous GLP-1. Linagliptin, a new drug in thisclass, selectively and reversibly inhibits DPP-4. Inclinical trials linagliptin 5 mg once daily significantlyreduced fasting and postprandial plasma glucoselevels. It is effective when used in monotherapy orin combination with metformin, sulfonylurea andpioglitazone. Linagliptin is well tolerated and hasneutral effects on body weight. There is no increasedrisk of hypoglycaemia attributed to linagliptin usedin monotherapy or combination therapy. Unlike otherDPP-4 inhibitors, linagliptin is excreted almost solely with bile, therefore it may be safely in patients withvarious degrees of renal impairment, even with endstage renal disease. It can be useful as an alternativetreatment for metformin in patients with diabetickidney disease or in metformin-intolerant subjects,where is can be used in monotherapy, as recommededby the Diabetes Poland in 2012.

Abstract

Preservation of insulin secretion in beta cells is oneof the objectives of type 2 diabetes treatment. Useof incretin-based drugs offers such possibilities. Thedipeptidyl peptidase 4 (DPP-4) inhibitors, the newclass of antidiabetic drugs, increases level of plasmaendogenous GLP-1. Linagliptin, a new drug in thisclass, selectively and reversibly inhibits DPP-4. Inclinical trials linagliptin 5 mg once daily significantlyreduced fasting and postprandial plasma glucoselevels. It is effective when used in monotherapy orin combination with metformin, sulfonylurea andpioglitazone. Linagliptin is well tolerated and hasneutral effects on body weight. There is no increasedrisk of hypoglycaemia attributed to linagliptin usedin monotherapy or combination therapy. Unlike otherDPP-4 inhibitors, linagliptin is excreted almost solely with bile, therefore it may be safely in patients withvarious degrees of renal impairment, even with endstage renal disease. It can be useful as an alternativetreatment for metformin in patients with diabetickidney disease or in metformin-intolerant subjects,where is can be used in monotherapy, as recommededby the Diabetes Poland in 2012.
Get Citation

Keywords

linagliptin, DPP 4 inhibitors, type 2 diabetes, renal impairment

About this article
Title

Linagliptin — new DPP-4 inhibitor. How much novelty does it bring to clinical practice?

Journal

Clinical Diabetology

Issue

Vol 1, No 2 (2012)

Pages

71-76

Published online

2012-06-01

Bibliographic record

Diabetologia Kliniczna 2012;1(2):71-76.

Keywords

linagliptin
DPP 4 inhibitors
type 2 diabetes
renal impairment

Authors

Maciej Pawłowski
Małgorzata Gilewska
Leszek Czupryniak

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

 

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl